Manufacturer
Boehringer Ingelheim
Contents
Dabigatran etexilate
Indication
75-mg & 110-mg cap Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip or knee replacement surgery (pVTE). 110-mg & 150-mg capReduction of the risk of stroke & systemic embolism in patients w/ non-valvular atrial fibrillation (SPAF). Deep vein thrombosis (DVT) & pulmonary embolism (PE), prevention of recurrent DVT & PE in adults.
Instruction
May be taken with or without food: Swallow whole, do not chew/crush.
Drug interaction
Unfractionated heparins & heparin derivatives, LMWH, fondaparinux, desirudin, thrombolytic agents, GPIIb/IIIa receptor antagonists, ticlopidine, dextran, sulfinpyrazone, vit K antagonists, itraconazole, diclofenac, amiodarone, verapamil, quinidine, systemic ketoconazole, dronedarone, rivaroxaban, prasugrel, ticagrelor, itraconazole, tracrolimus, cyclosporine, ritonavir, tipranavir, nelfinavir, saquinavir, clarithromycin; P-glycoprotein inhibitor substrate (eg, digoxin), inducers (eg, rifamipicin, St. John's wort or carbamazepine). SSRIs.
Malaysia
